Claims for Patent: 10,087,253

Summary for Patent: 10,087,253

Title:	Monoclonal antibody capable of binding integrin alpha 10 beta 1
Abstract:	The present invention provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 and a hybridoma cell line deposited at the Deutsche Sammlung von Microorganismen und Zellkulturen GmbH under the accession number DSM ACC2583. Furthermore, the present invention also provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 produced by the hybridoma cell line deposited. Methods and uses of said antibody or a fragment thereof in identifying and selecting cells of a chondrogenic nature for treatment purposes, in particular for the identification and isolation of chondrocytes, mesenchymal progenitor cells and embryonic stem cells for tissue engineering of cartilage, or for identifying diagnostic and therapeutic tools in studying the biological role and the structural/functional relationships of the integrin alpha10beta1 with its various extracellular matrix ligands are also included.
Inventor(s):	Lundgren-Akerlund; Evy (Bjarred, SE)
Assignee:	Xintela AB (Lund, SE)
Application Number:	15/156,032
Patent Claims:	1. An administration vehicle comprising a monoclonal antibody or a fragment thereof, wherein the antibody or fragment thereof is capable of binding specifically to the extracellular I-domain of the integrin alpha10 chain, and wherein the antibody or the fragment thereof is produced by a hybridoma cell line deposited at the Deutsche Sammlung von Microorganismen and Zellkulturen GmbH under the accession number DSM 25 ACC2583, wherein the antibody or the fragment thereof is conjugated to a delivery vehicle. 2. The administration vehicle of claim 1, wherein the delivery vehicle is a vector. 3. The administration vehicle of claim 2, wherein said vector is a viral vector selected from the group consisting of retrovirus, adenovirus, adeno-associated virus (AAV), herpes simplex virus and lentivirus. 4. The administration vehicle of claim 2, wherein said vector is an adenoviral vector. 5. The administration vehicle of claim 1, wherein the monoclonal antibody or the fragment thereof is of murine origin. 6. The administration vehicle of claim 1, wherein the fragment binding to the extracellular I-domain of integrin alpha10beta1 is selected from the group consisting of Fv, Fab, Fab', F(ab')2 and single chain antibodies. 7. The administration vehicle of claim 1, wherein the delivery vehicle is a gene delivery system. 8. The administration vehicle of claim 7, wherein the gene encodes molecules selected from a group consisting of growth factors, transcription factors, signaling molecules, enzyme inhibitors and promoters for genes of extracellular matrix molecules. 9. The administration vehicle of claim 8, wherein the gene is a gene encoding a growth factor selected from the group consisting of insulin-like growth factor-1 (IGF-1), transforming growth factor-beta (TGF-.beta.), fibroblast growth factor, hepatocyte growth factor, platelet-derived growth factor, parathyroid hormone-related peptide, Indian hedgehog protein, sonic hedgehog protein and bone morphogenic proteins. 10. The administration vehicle of claim 8, wherein the gene is a gene encoding a transcription factor selected from the group consisting of SOX-9, SOX-5 and SOX-6.

Details for Patent 10,087,253

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2023-04-14